X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DA-1726 is a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
Lead Product(s): Oxyntomodulin Analog
Therapeutic Area: Nutrition and Weight Loss Product Name: DA-1726
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual agonist, which is currently being evaluated for the treatment of obesity.
Lead Product(s): DA-1726
Therapeutic Area: Nutrition and Weight Loss Product Name: DA-1726
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist. It is under phase 2 clinical development in combination with sitagliptin, a DPP4 inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Lead Product(s): DA-1241,Sitagliptin Phosphate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DA-1241
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
Under the agreement, NeuroBo will out-license the worldwide rights, outside of Korea, for NB-01/DA-9801 (dioscorea extract) for the treatment of painful diabetic neuropathy to MThera.
Lead Product(s): Dioscorea Extract
Therapeutic Area: Neurology Product Name: NB-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MThera Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 02, 2023
Details:
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, which is being investigated as a standalone or combination therapy for nonalcoholic steatohepatitis (NASH) and type 2 diabetes.
Lead Product(s): DA-1241
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DA-1241
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D.
Lead Product(s): DA-1241
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DA-1241
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
Under the license agreement, NeuroBo has obtained an exclusive license to develop and commercialize DA-1241 (a novel GPR119 agonist) and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH), obesity and type 2 diabetes.
Lead Product(s): DA-1241
Therapeutic Area: Endocrinology Product Name: DA-1241
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Dong-A ST Co., Ltd.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 08, 2022
Details:
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucose metabolism, lipid metabolism and weight loss.
Lead Product(s): DA-1241
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DA-1241
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dong-A ST Co., Ltd.
Deal Size: $37.0 million Upfront Cash: $22.0 million
Deal Type: Licensing Agreement September 15, 2022
Details:
ANA001 is a proprietary oral niclosamide formulation in development as a treatment for patients with COVID-19. Niclosamide has antiviral and anti-inflammatory properties, and a well-understood safety profile in humans.
Lead Product(s): Niclosamide,Gemcabene
Therapeutic Area: Infections and Infectious Diseases Product Name: ANA001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Details:
NeuroBo Pharmaceuticals has received approval of an amendment to its Contingent Value Rights (CVR) agreement from a majority of the holders of a majority of the outstanding CVRs, incentivizing the evaluation of Gemcabene as a treatment for COVID-19.
Lead Product(s): Niclosamide,Gemcabene
Therapeutic Area: Infections and Infectious Diseases Product Name: ANA001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
